Patient groupa Neonate Infant Toddler Child Adolescent
Rocuronium dose (mg/kg) 0.45
(n=5)		 0.6
(n=7)		 1.0
(n=6)		 0.45
(n=9)		 0.6
(n=6)		 1.0
(n=5)		 0.45
(n=18)		 0.6
(n=16)		 1.0
(n=15)		 0.45
(n=16)		 0.6
(n=21)		 1.0
(n=16)		 0.45
(n=18)		 0.6
(n=16)		 1.0
(n=15)
Gender, n (%)
    Female
      
    Male
1
(20.0)
4
(80.0)

1
(14.3)
6
(85.7)

1
(16.7)
5
(83.3)

4
(44.4)
5
(55.6)

0
(0.0)
6
(100)

2
(40.0)
3
(60.0)

5
(27.8)
13
(72.2)

3
(18.8)
13
(81.3)

6
(40.0)
9
(60.0)

6
(37.5)
10
(62.5)

14 (66.7)
7
 (33.3)

7
(43.8)
9
(56.3)

7
 (38.9)
11
(61.1)

7
(43.8)
9
(56.3)

7
(46.7)
8
(53.3)
Ageb
    Mean
    (SD)
0.26 (0.14)
0.46
(0.23)
0.41 (0.25)
2.05 (0.82)
2.45
(0.37)
1.72 (0.73)
10.69
(4.59)
12.82
(6.06)
11.99 (4.98)
5.12 (2.65)
6.03
(2.18)
5.77
(2.34)
15.05
(1.73)
14.32
(1.54)
14.60
(1.82)
Weight (kg)
    Mean
    (SD)
3.48
(0.22)
3.61 (0.25)
3.37
(0.32)
5.19
(1.09)
5.48
(1.06)
4.62
(0.37)
8.74 (1.51)
9.56 (1.97)
9.10 (1.46)
22.38 (14.89)
22.89
(10.26)
19.98 (6.22)
58.98 (14.15)
55.98 (15.08)
55.13 (13.72)
Race, n (%)
    Asian

    Black

    White
0
(0)
1
(20.0)
4
(80.0)
1
(14.3)
1
(14.3)
5
(71.4)
0
(0)
0
(0)
6
(100)
0
(0)
0
(0)
9
(100)
1
(16.7)
1
(16.7)
4
(66.7)
0
(0)
0
(0)
5
(100)
0
(0)
2
(11.1)
16
(88.9)
0
(0)
2
(12.5)
14
(87.5)
2
(13.3)
1
(6.7)
12
(80.0)
0
(0)
2
(12.5)
14 (87.5)
1
(4.8)
8
(38.1)
12
(57.1)
1
(6.3)
4
(25.0)
11
(68.8)
0
(0)
3
(16.7)
15
(83.3)
0
(0)
2
(12.5)
14
(87.5)
1
(6.7)
2
(13.3)
12
(80.0)
ASA Class
    1

    2

    3
1
(20.0)
1
(20.0)
3
(60.0)
0
(0.0)
2
(28.6)
5
(71.4)
1
(16.7)
2
(33.3)
3
(50.0)
4
(44.4)
5
(55.6)
0
(0)
3
(50.0)
2
(33.3)
1
(16.7)
4
(80.0)
1
(20.0)
0
(0)
6
(33.3)
10
(55.6)
2
(11.1)
5
(31.3)
10
(62.5)
1
(6.3)
4
(26.7)
9
(60.0)
2
(13.3)
7
(43.8)
8
(50.0)
1
(6.3)
8
(38.1)
10
(47.6)
3
(14.3)
8
(50.0)
5
(31.3)
3
(18.8)
7
(38.9)
10
(55.6)
1
(5.6)
8
(50.0)
8
(50.0)
0
(0)
8
(53.3)
6
(40.0)
1 
(6.7)
aNeonates: birth to <28 days, infants: 28 days to ≤3 months, toddlers: >3 months to ≤2 years, children: >2 years to ≤11 years, and adolescents: >11 to ≤17 years;
bAge in months for neonates, infants and toddlers; in years for children and adolescents; ASA: American Society of Anesthesiologists.
Table 1: Summary of patient baseline characteristics (all subjects receiving rocuronium; n=189).